Association between statin use and disease-specific endometrial cancer survival

Arsdale, A.R. Van; Einstein, Mark H.; Kaur, Gurpreet; Strickler, H.; Moadel, Alyson B.; Girda, Eugenia; Goldberg, Gary L.; Nevadunsky, Nicole S.

doi:10.1016/j.ygyno.2015.01.074

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After screening the titles and abstracts, 21 potentially relevant records were retrieved for further review. Of these, we excluded 11 studies for the following reasons: 4 did not report the survival outcomes in gynecologic cancers [ 18 – 21 ], 4 used overlapping data [ 22 – 25 ], and 3 did not have usable data [ 26 – 28 ]. We identified no additional ongoing trials from trial registers.…”

Section: Resultsmentioning

confidence: 99%

Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis

Xie

Huang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Previous studies investigating the association between statin use and survival outcomes in gynecologic cancers have yielded controversial results. We conducted a systematic review and meta-analysis to evaluate the association based on available evidence. We searched the databases of the Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and PubMed from inception to January 2017. Studies that evaluated the association between statin use and survival outcomes in gynecologic cancers were included. Pooled hazard ratios (HRs) for overall survival, disease-specific survival and progression-free survival were calculated using a fixed-effects model. A total of 11 studies involving more than 6,920 patients with endocrine-related gynecologic cancers were identified. In a meta-analysis of 7 studies involving 5,449 patients with endocrine-related gynecologic cancers, statin use was linked to improved overall survival (HR, 0.71; 95% confidence interval [CI], 0.63 to 0.80) without significant heterogeneity (I2 = 33.3%). Statin users also had improved disease-specific survival (3 studies, HR, 0.72; 95% CI, 0.58 to 0.90, I2 = 35.1%) and progression-free survival (3 studies, HR, 0.68; 95% CI, 0.49 to 0.93, I2 = 33.6%) in endocrine-related gynecologic cancers. Our findings support that statin use has potential survival benefits for patients with endocrine-related gynecologic cancers. Further large-scale prospective studies are required to validate our findings.

show abstract

Section: Resultsmentioning

confidence: 99%

Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis

Xie

Huang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Among the 21 articles investigating the effect of statins on the prognosis of endometrial cancer, 6 were excluded for not reporting the survival rate of patients with EC, [20–25] and 3 were excluded for lack of useful data. [26–28] Two abstracts [29,30] and 1 meta-analysis [31] were also excluded. Ultimately, 8 articles and 1 abstract were included in the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

The association between statin use and endometrial cancer survival outcome

Liu

Sun

et al. 2018

Medicine

View full text Add to dashboard Cite

Background: Previous studies on the association between statin use and survival outcomes in gynecologic cancers have presented conflicting results. No independent studies to elucidate the association between statin use and survival outcomes of endometrial cancer (EC) have been conducted. Methods: To gather updated evidence, we carried out an extensive literature search on Medline (PubMed and OvidSP), Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), wanfang data, and Vip network to identify all potential studies on the effect of statins on the prognosis of endometrial carcinoma. The design and quality of all studies were evaluated, and a fixed-effects model was used to calculate pooled hazard ratios (HRs) for overall survival (OS) and disease-specific survival (DSS). Results: Of the 219 articles screened, 9 articles were eligible, including 8 articles and 1 abstract. A total of 5923 patients with endometrial cancer who used statins were identified. Statin use was related to increased overall survival (HR, 0.80; 95% confidence interval [CI], 0.66–0.95, without significant heterogeneity, I 2 = 52%, P = .080). Statin users also had increased disease-specific survival (HR, 0.69; 95% CI, 0.61–0.79, I 2 = 0.0%). Conclusion: Statins are beneficial to the survival outcome of patients with endometrial cancer. The selection of statins as a 1st-line agent seems justified for endometrial carcinoma.

show abstract